I first read about MBP8298 last year when researching treatments for MS. Since it is used for Secondary Progressive, I was very interested. I took articles to my husband's neurologist. He is never interested in Clinical Trials. Doesn't like that patient may be on a Placebo, etc. etc. The first trials were conducted in Europe and Canada - MAESTRO-01.
As Lars said, just google or read some of the other sites that research new treatments.
Here is a little info on MAESTRO-03 which is being conducted in U.S. --
BioMS Medical Corp., a leading developer in the treatment of multiple sclerosis (MS), today announced that more than 133 patients have been enrolled in its MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.
"There has been overwhelming enthusiasm and support from the MS community for our U.S. Phase III trial," said Kevin Giese, President and CEO of BioMS Medical. "With the ramp-up in the initiation of participating clinical sites and patient recruitment we are on track to complete enrollment in the first half of 2008."
The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).
Source: BioMS Medical Corp (12/11/07)